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Abstract
Background: Doxorubicin is considered one of the most potent established chemotherapeutics
in the treatment of liposarcoma; however, the response rates usually below 30%, are still
disappointing. This study was performed to identify gene expression changes in liposarcoma after
doxorubicin treatment.
Methods: Cells of 19 primary human liposarcoma were harvested intraoperatively and brought
into cell culture. Cells were incubated with doxorubicin for 24 h, RNA was isolated and differential
gene expression was analysed by the microarray technique.
Results: A variety of genes involved in apoptosis were up and down regulated in different samples
revealing a heterogeneous expression pattern of the 19 primary tumor cell cultures in response to
doxorubicin treatment. However, more than 50% of the samples showed up-regulation of pro-
apoptotic genes such as TRAIL Receptor2, CDKN1A, GADD45A, FAS, CD40, PAWR, NFKBIA, IER3,
PSEN1, RIPK2, and CD44. The anti-apoptotic genes TNFAIP3, PEA15, Bcl2A1, NGFB, and BIRC3 were
also up-regulated. The pro-apoptotic CD14, TIA1, and ITGB2 were down-regulated in more than
50% of the tumor cultures after treatment with doxorubicin, as was the antiapoptotic YWHAH.
Conclusion: Despite a correlation of the number of differentially regulated genes to the tumor
grading and to a lesser extent histological subtype, the expression patterns varied strongly;
however, especially among high grade tumors the responses of selected apoptosis genes were
similar. The predescribed low clinical response rates of low grade liposarcoma to doxorubicin
correspond to our results with only little changes on gene expression level and also divergent
findings concerning the up- and down-regulation of single genes in the different sarcoma samples.
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Background
Together with malignant fibrous histiocytoma (not other-
wise specified sarcoma, NOS), liposarcoma represents the
most common entity of soft tissue sarcomas and accounts
for approximately 20% of sarcomas in adults [1-3].
Although surgery and radiation therapy could achieve
good results concerning local control, distant metastatic
disease remains a therapeutic dilemma limiting survival
[4,5]. With a maximum response rate of approximately
20% the effects of cytostatics on liposarcoma are still dis-
appointing [6-8]. The most favoured chemotherapeutics
for treatment of advanced soft tissue sarcoma, including
liposarcoma, are ifosfamide and doxorubicin, but the data
for ifosfamide differ with respect to improvement of local
control and survival [9-11]. Although meta-analysis of 14
randomised trials found that doxorubicin treatment was
associated with a 10% improvement of recurrence free
survival, the overall survival could not be improved [12-
14]. In carcinomas, multiple mechanisms of drug resist-
ance on the molecular level have been characterized
[15,16] including over-expression of p53 [17-20], MDR1
(multidrug resistance gene 1) [20-22], MRP1 (multidrug
resistance-associated protein), the induction of DNA
repair [20] and many others involving tumor suppressor
genes, oncogenes, cell cycle regulators, transcription fac-
tors, growth factor receptors, and cell death regulators.
Only little is known about the molecular basis of drug
resistance in soft tissue sarcomas and studies on the effect
of cytostatics on gene expression, especially in liposarco-
mas [23-27], are rare. Comprehensive knowledge of the
differential expression patterns induced by cytotoxic
drugs may be useful for examining the molecular basis of
drug effects and also drug resistance. Because of the lim-
ited comparability of established purchasable sarcoma
cell lines to in vivo tumors, we primarily harvested liposa-
rcoma cells from resection specimens, incubated the cul-
tured cells with doxorubicin and evaluated the changes in
gene expression with a focus on genes related to apoptotic
pathways. To the authors' knowledge, to date there are no
studies that examined the effects of doxorubicin on pri-
mary human liposarcoma on a molecular basis.
Methods
Primary human liposarcoma tumor samples of at least 1
cm3 were harvested intraoperatively from patients under-
going resection of an already diagnosed liposarcoma and
immediately processed under sterile conditions. Seven
atypical lipomas (low grade sarcomas), four dedifferenti-
ated, four pleomorphic, three myxoid/round cell, and one
myxoid liposarcoma were included. The grading of the
tumors ranged from GI to GIII (GI: 4, GII: 8, GIII: 7). The
probes were derived from primary tumors in 12, from
recurrent tumors in six, and from metastasis in one case.
Nineteen primary human liposarcoma cultures were iso-
lated by dissecting the tumor and digesting the minced
samples enzymatically with 10 ml each of collagenase and
dispase (10 mg/ml). The single cell suspension was
depleted of red blood cells and cellular debris by centrifu-
gation through a Ficoll-Hypaque density gradient. Liposa-
rcoma cells were diluted and cultured during the whole
experiment with Leibovitz's L-15 medium, supplemented
with 2.0 mM glutamine and 10% fetal bovine serum in a
humidified atmosphere in free air exchange with atmos-
pheric air. Cells were seeded at a density of 2 × 106 in 25
cm2flasks; 24 h later, after having grown to a subconfluent
layer, cell cultures were incubated with doxorubicin (0.5
μg/ml) for 24 h and equal volume of PBS as control [28-
30].
Oligonucleotide microarray analysis
For microarray analyses we used the Affymetrix Gene Chip
platform employing a standard protocol for sample prep-
aration and microarray hybridization that has been
described in detail previously [26,31]. Briefly, total RNA
was converted into double-stranded cDNA using an oligo-
deoxythymidine primer containing the T7 RNA polymer-
ase binding site (5'-GCATTAGCGGCCGCGAAAT-
TAATACGACTCACTATAGGGAGA – (dT)21V-3') (MWG
Biotech, Ebersberg, Germany) for first strand synthesis.
After generation of double-stranded cDNA from the first-
strand cDNA, biotinylated cRNA was synthesized by in
vitro  transcription using the BioArray High Yield RNA
Transcript Labeling Kit (Enzo Diagnostics, New York,
USA). Labeled cRNA was purified on RNeasy columns
(Qiagen, Hilden, Germany) and fragmented and hybrid-
ized to HG-U133A microarrays (Affymetrix, Santa Clara,
USA). The arrays were washed and stained according to
the manufacturer's recommendation and finally scanned
in a GeneArray scanner 2500 (Agilent, Santa Clara, USA).
Array images were processed to determine signals and
detection calls (Present, Absent, Marginal) for each
probeset using the Affymetrix Microarray Suite 5.0 soft-
ware (MAS 5.0; statistical algorithm). The clustering was
performed unsupervised. Pairwise comparisons of treated
versus  control samples were carried out with MAS 5.0,
which calculates the significance (change p-value) of each
change in gene expression based on a Wilcoxon ranking
test. To limit the number of false positives, we restricted
further target identification to those probesets, which
received at least one present detection call in the treated/
control pair. Each single microarray analysis was derived
from one cell culture. The treated cells were compared to
the control. Probesets exhibiting a signal log2 ratio > 1.0
and a change p-value < 0.004 or a signal log2 ratio < -1.0
and a change p-value > 0.996 (corresponding to 2-fold
up- or down-regulation) were identified by filtering using
the Affymetrix Data Mining Tool 3.0 (Table 1). Addition-
ally unsupervised clustering was performed between the
19 control tumor samples.B
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Table 1: Summarized patients' data
Patient Gender Age at 
operation
Site Size in cm Histological subtype Responder 
type
Grading Specimen 
character
Previous 
radiation
Previous 
chemotherapy
1 female 69 years lower arm 4.5 × 3.5 × 2.2 atypical lipoma with 
partly dedifferentiated 
areas
low G2 local recurrence no no
2 female 74 years Thigh 14.5 × 7.5 × 9 myxoid/roundcell 
liposarcoma
high G3 primary tumor no no
3 female 70 years upper arm 3 × 5 × 6 atypical lipoma low G1 primary tumor no no
4 male 74 years Thigh 16.5 × 9 × 7 dedifferentiated 
liposarcoma
medium G2 primary tumor no no
5 male 38 years Knee 8.3 × 4 × 7 myxoid liposarcoma high G3 primary tumor yes no
6 female 58 years pelvis retro-
peritoneal
4 × 7 × 9 myxoid/roundcell 
liposarcoma
high G3 metastasis no no
7 male 37 years Thigh 7 × 14 × 9 myxoid/roundcell 
liposarcoma
medium G2 primary tumor no yes
8 female 85 years lower arm 11 × 8 × 4 pleomorphic 
liposarcoma
high G3 primary tumor no no
9 male 53 years Thigh 10 × 3 × 5 atypical liposarcoma low G2 local recurrence yes no
10 male 76 years Thigh 3.5 × 3 × 3 dedifferentiated 
liposarcoma
high G3 local recurrence yes no
11 female 57 years Thorax 4.9 × 4 × 3 pleomorphic 
liposarcoma
high G3 local recurrence no no
12 female 76 years Thigh 38.5 × 17.5 × 6 atypical lipoma low G1 primary tumor no no
13 female 74 years Thigh 7 × 6 × 4 dedifferentiated 
liposarcoma
medium G2 primary tumor no no
14 female 70 years Thorax 1.9 × 1.3 × 1 pleomorphic 
liposarcoma
medium G2 residual tumor no no
15 male 70 years Thigh 9 × 3 × 6 atypical lipoma medium G1 primary tumor no no
16 male 60 years Thigh 7.5 × 6 × 5.5 pleomorphic 
liposarcoma
high G3 primary tumor no no
17 female 78 years Thigh 13 × 10 × 6 atypical lipoma with 
partly dedifferentiated 
areas
high G2 local recurrence yes no
18 female 67 years Thigh 35 × 15 × 12 atypical lipoma low G1 primary tumor no no
19 male 60 years upper arm 9,9 × 7 × 7 dedifferentiated 
liposarcoma
medium G2 local recurrence yes noBMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
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Genes associated with apoptotic pathways were selected
based on Gene Ontology (GO)-analysis [32].
Expression changes were correlated to the grading and the
histological sub-entity of the tumors. Only tumor samples
were included in the final analysis whose gross sections
were diagnosed as liposarcomas by an experienced soft
tissue pathologist.
According to the number of differentially expressed genes
after incubation with doxorubicin, liposarcomas were cat-
egorized into high (n > 2000), intermediate (100 < n <
1000) and low responders (n < 100). The results were
uploaded to NCBI GEO, number GSE12972 http://
www.ncbi.nlm.n
ih.gov/geo/query/acc.cgi?acc=GSE12972.
Real-time PCR for microarray data validation
Microarray data validation was performed for selected
gene products with relevant up-regulation in more than
ten out of the 19 liposarcoma probes (CD40, CDKN1A,
FAS, GADD45A, NFKBIA, PAWR, TNFAIP3, and
TNFRSF10B) or relevant down-regulation in at least ten
probes (YWHaH, PPP3CA, and ITGB2). CD14 and TIA
were not tested because no high quality PCR assays were
purchasable.
Total RNA (2 μg) was reverse transcribed using the High
Capacity cDNA Archive Kit (Applied Biosystems). Real-
time PCR was done with a 7900HT SDS system (Applied
Biosystems) in 20 μl reaction volume containing 1× Mas-
ter Mix, 1 μl assay and cDNA equivalent to 2 ng total RNA.
All reagents and realtime PCR assays (m1 type only;
CD40_Hs00386848_1, CDKN1A_Hs00355782_m1, FAS
_Hs00236330_m1, GADD45A_Hs00169255_m1, ITGB2
_Hs00164957_m1, NFKBIA_Hs00153283_m1, PAWR_H
s00169332_m1, PPP3CA_Hs00174223_m1, TNFAIP3_H
s00234713_m1, TNFRSF10B_Hs00366272_m1, YWHaH
_Hs00607046_m1) used were purchased from Applied
Biosystems. Reactions were performed in duplicates and
analysed by the deltadeltaCT method. Human GAPD was
used for normalization. Pearson correlation of the micro-
array and the rtPCR data was calculated using SPSS Ver-
sion 15.0 for Windows (SPSS Inc., Chicago, USA).
Results
Sixteen tumors were located at the extremities, three at the
trunk. The tumors diameters ranged from 1 cm to 38,5
cm. Twelve primary cultures were harvested from primary
tumors, 6 from local recurrences, and 1 from a metastatic
tumor. The majority of tumors were high grade (G2-3);
only 4 were diagnosed low grade (G1). Atypical lipoma or
highly differentiated liposarcoma was the most common
histological subentity (n = 7) followed by dedifferentiated
(n = 4) and pleomorphic (n = 4), myxoid/rundcell (n = 3)
and myxoid (n = 1) liposarcoma. All low grade tumors
were diagnosed as atypical lipoma, whereas 3 atypical
lipomas were categorized as G2 tumors because of aggres-
sive growth or localized areas of dedifferentiation. The
other subentities were all categorized as high grade
tumors (G2-3). A summary of the patients' data is given in
table 1.
Hierarchical clustering of expression profiles from
untreated samples did not clearly separate according to
histological subtype or grading, but revealed two major
branches, which showed some enrichment for G3 (left)
and G2 tumors (right) (fig. 1).
According to the number of differentially expressed genes
n after incubation with doxorubicin, the 19 liposarcomas
were categorized into high (n > 2000), intermediate (100
< n < 1000) and low responders (n < 100). All poorly dif-
ferentiated (G3) tumors were high responders; G2 tumors
were predominantly intermediate responders; and, most
of the G1 tumors were low responders. A heatmap of all
differentially expressed genes after 24 h of doxorubicin
tratment shows heterogeneous response patterns (fig. 2).
Correlating the overall expression changes with the histo-
logical subtype showed that most of the atypical lipomas
were low responders (5 low, 1 medium, 1 high), dediffer-
entiated were predominantly medium responders (3
medium, 1 high), most myxoid/roundcell and myxoid
liposarcomas as well as the pleomorphic liposarcomas
were high responders (3 high, 1 medium each). The high
grade sarcomas (G3) clustered closely together.
The alteration of gene expression related to apoptotic
pathways correlated to the categorisation given above.
Low responders also did also not respond with relevant
gene expression changes of "apoptosis genes" whereas the
high responders showed a significantly different gene
expression profile concerning apoptosis related genes
compared to the untreated control. In all, we found 464
genes with expression changes that are related to apop-
totic pathways. The single genes that were differentially
expressed in the medium and high responder group only
partly overlapped with the low responder group. The het-
erogeneity of the response patterns of apoptotis related
genes is illustrated in figure 3.
Although the diversity of changes in gene expression was
large, some apoptosis related genes showed similar
expression changes in the tumor samples, especially the
high grade tumors (G2 and G3) or high responders. Figure
4 focus on expression changes in these genes. The apopto-
sis related genes most often affected by doxorubicin treat-
ment are mentioned below. Due to their large number, we
only refer to the genes that were differentially (up- orBMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
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Figure 1 (see legend on next page)BMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
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down-) regulated in more than 50% of the probes (sam-
ples). Some of the genes that were found up-regulated in
the majority of the probes (tumors) could be found
down-regulated in some other samples and vice versa. The
heatmaps provided illustrate the similarity of the expres-
sion of these selected genes in correlation to responder
group, grading, and histological subtype (fig. 4. The
intrinsic and the extrinsic apoptotic pathway, as well as
transcription factors and genes, so far only marginally
associated with apoptotic pathways. A summary of the
genes and their expression changes is given in table 2 and
3.
The results of the microarray analysis were validated using
rtPCR. The general Pearson correlation of the expression
changes measured in all selected genes in the tumor
probes was high (0.913). The correlation coefficients for
the single candidate genes are given in table 4.
Discussion
Gene expression profiling has already been helpful in cat-
egorizing distinct subtypes of sarcomas by profile cluster-
ing [33-35] and identifying subtype specific changes in
gene expression in liposarcoma, e.g. abnormal expression
of cell cycle regulators in FUS-DDIT3 carrying liposarco-
mas [34,36-43] and even provided potential targets for
new therapeutic agents like important mediators in cell
cycle regulation, e.g. MDM2 [44-48].
Gene expression profiling studies on liposarcomas have
already shown that this entity presents a somewhat simi-
lar expression pattern with malignant fibrous histiocy-
toma and leimyosarcoma [31,49] and that highly
differentiated lesions cluster with lipoma whereas the
dedifferentiated tumors cluster with myxoid/round cell
liposarcomas [50]; however no clear correlation between
expression patterns and histological subtype could be
detected [37]. Another difficulty in the assessment of gene
expression profiles is the inter- and intra-tumoral hetero-
geneity. Several subtypes with different expression pat-
terns and histologic features can often be found within
one same tumor [51,52].
Liposarcomas are classified into several types based on
histological findings and cytological aberrations – well
differentiated (atypical lipoma), dedifferentiated,
myxoid, round cell tumors and pleomorphic. The risk of
distant metastasis grows with the grading of the lesion to
up to 75% in pleomorphic sarcoma. Myxoid tumors with
a greater than 5% round cell component, most dedifferen-
tiated, and pleomorphic liposarcomas are considered
high grade lesions [4,53-55].
There are no markers to clearly identify liposarcoma cells.
S100, CD34, and others may be helpful (as well as cytoge-
netic techniques) as they can identify aberrations indicat-
ing myxoid/round cell sarcoma; however, they cannot
identify liposarcoma cells with absolute certainty [56]. In
our series, we relied on a proper tumor dissection and
preparation of the specimens to ensure, the isolated tissue
mainly consisted of liposarcoma cells as previously
described by Sreekantaiah et al. [57] and Lehnhardt et al
[58], but have to admit that results may be partly falsified
by residual tumor stroma cells accidentally co-cultivated
within the liposarcoma samples.
Liposarcoma cells showed diverse gene expression pat-
terns before and after incubation with doxorubicin.
Tumors of the same histologic subgroup did not cluster
together concerning their overall gene expression. The cor-
relation of the number of differentially regulated genes to
the tumor grading, and, to a lesser extent, to the histolog-
ical subgroup after doxorubicin incubation, may be
caused by the tumor associated up-regulation of cell
metabolism and the therefore greater effect of any interfer-
ence. The overall expression patterns and the ones of the
apoptosis related genes were also very heterogenous (fig.
2, 3). This finding is concordant to the results of other
studies with soft tissue sarcoma cells [59] and may partly
be explained by the known inter- and intratumoral heter-
ogeneity in soft tissue sarcomas [51,60].
Interestingly the myxoid and the myxoid/round cell
liposarcomas clustered together in figure 2 and 3 except
from the tumor 7 that was pre-treated with chemotherapy.
Unsupervised hierarchical cluster analysis of the 19 primary tumor cell cultures without doxorubin treatment Figure 1 (see previous page)
Unsupervised hierarchical cluster analysis of the 19 primary tumor cell cultures without doxorubin treatment. 
Gene signal intensities were normalized to the mean signal of all samples, log2 transformed and subjected to hierarchical clus-
tering (UPGMA, Spotfire) and correlation as a similarity measure. Horizontal rows represent individual genes; vertical columns 
represent individual samples. Black indicates average signal intensity, brightest red ≥ 4-fold up-regualtion, brightest green ≥ 4-
fold down-regulated gene expression relative to the mean. Only probesets receiving P detection calls in 6 or more samples and 
a stander deviation of normalized signals > 0.2 were considered. (7239 retained). The dendogram at the top of the matrix indi-
cates the degree of similarity between tumor samples (the higher the dendogramm, the lower the similarity). Two major clus-
ters were identified as indicated. MR: Myxoid/Roundcell Liposarcoma, PL: Pleomorphic Liposarcoma, AL: Atypical Lipoma, ML: 
Myxoid Liposarcoma, DL: Dedifferentiated Liposarcoma, low: low responder group, medium: medium responder group, high: 
high responder group.BMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
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Figure 2 (see legend on next page)BMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
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If that is a coincidence or may be interpreted as a kind of
selectional process that could have eliminated the high
grade parts of the tumor leaving the residual to cluster
closer to the low grade sarcomas can not be determined.
The predescribed low clinical response rates of low grade
sarcoma correlate to our findings that low grade liposar-
coma, especially atypical lipoma, showed almost no
response to doxorubicin on gene expression level [61].
However, some expression changes in response to doxo-
rubicin treatment, observed especially in the high
responder and in the high grade group were similar and
are focussed on the figure 4. According to the large
number of apoptosis related genes, we identified the first
five ones that were differentially expressed in more than
50% of the samples and limit further explanation to these
with special reference to apoptotic function in sarcoma or
previous reports concerning doxorubicin treatment,
although the understanding of their exact functions is lim-
ited. The up-regulated genes beyond the mentioned five
are summarized in table 5.
Up-regulated genes
As previously shown, doxorubicin could overcome TRAIL
resistance in a variety of sarcoma cell lines. An up-regula-
tion of the TRAIL-R2, increasing the susceptibility to
apoptosis inducing agents such as TRAIL, may be a possi-
ble explanation [62-65], as we found the Trail receptor 2
gene expression increased in 15 probes.
The second most frequently up-regulated gene was cyclin-
dependent kinase inhibiton 1A (CDKN1A), a down-
stream target of p53, has has already been shown to be
involved in cell cycle arrest and apoptosis induction by
doxorubicin in sarcoma cells. CDKN1A can act as aposi-
tive regulator of senescence-like terminal proliferation
arrest, but its function seems neither sufficient nor abso-
lutely required for a treatment response to doxorubicin in
tumor cells, especially soft tissue sarcoma [66-70].
GADD45A, a potent inhibitor of the c-Jun N-terminal
kinase (JNK) cascade and NFKBIA, inhibits transcription
factors associated with tumor growth [71-74] and was up-
regulated by doxorubicin in 12 probes. In a variety of soft
tissue sarcoma cell lines GADD45A was found to increase
cell cycle arrest and apoptosis {Zhu, 2008 #165}. For
rhabdomyosarcoma, increased GADD45A has previously
been associated with less aggressive tumor behaviour
[75].
FAS, a member of the tumor necrosis factor receptor fam-
ily, seems to be an important mediator in doxorubicin
induced apoptosis. Its effects were shown to be dependant
on metalloproteinases in soft tissue sarcoma and Ewing
sarcoma. These metalloproteinases have been associated
with aggressive tumor behaviour and may promote inva-
siveness and the occurrence metastasis of malignant cells
[76-78].
Another member of the TNF receptor superfamily, CD40,
was also up-regulated by doxubicin in our experiments.
To the authors' knowledge, CD40 has not yet been associ-
ated with doxorubicin treatment in liposarcoma, but its
expression in soft tissue sarcoma was associated with an
unfavourable outcome [79], whereas Lodge et al. could
show a beneficial effect of antibody mediated CD40 acti-
vation in elimination of fibrosarcoma in nude mice [80].
Down-regulated genes
Among the down-regulated genes related to apoptotic
pathways CD14, a receptor marking apoptotic cells was
found in 8 probes. Increased CD14 has been associated
with apoptosis induction and cell clearance, especially
mediated by macrophages, but is expressed by a variety of
other cells too [81-83]. Its role in terms of cell death medi-
ation in sarcoma cells has not yet been examined, there-
fore interpretation of this finding remains difficult.
TIA-1, which encodes an RNA-binding protein with trans-
lation-regulatory functions has already been reported to
be up-regulated in tumor specimens post-treatment with
TNF alpha in soft tissue sarcomas. It was further hypothe-
sized that TIA-1 could mediate death receptor mediated
apoptosis in soft tissue sarcoma and that its overexpres-
Heatmap of total gene expression changes and cluster analysis after incubation with doxorubicin for 24 h Figure 2 (see previous page)
Heatmap of total gene expression changes and cluster analysis after incubation with doxorubicin for 24 h. Hor-
izontal rows represent individual genes; vertical columns represent individual samples. Color range: Brightest red (Change call 
increased (change p-value < 0.002) and Signal Log Ratio > 1): SLR = >2 (4× or higher), Black: SLR = 0 (no change); not visible as 
a consequence of the filtering process, Brightest green (Change call decreased (change p-value > 0.998) and Signal Log Ratio < 
-1): SLR < -2 (0.25× or smaller). Grey: no value (requirements for a reliably measured target not met). Calculated in Affymetrix 
comparison analysis (MAS5.0 algorithm) and at least one present call in the two síngle array analyses compared in the compar-
ison analysis. The dendogram at the left side indicates the degree of similarity among the selected genes according to their 
expression patterns (the higher the dendogramm, the lower the similarity). MR: Myxoid/Roundcell Liposarcoma, PL: Pleomor-
phic Liposarcoma, AL: Atypical Lipoma, ML: Myxoid Liposarcoma, DL: Dedifferentiated Liposarcoma, low: low responder 
group, medium: medium responder group, high: high responder group.BMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
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Heatmap of expression changes of genes related to apoptotic pathways after incubation with doxorubicin for 24 h Figure 3
Heatmap of expression changes of genes related to apoptotic pathways after incubation with doxorubicin for 
24 h. Horizontal rows represent individual genes; vertical columns represent individual samples (left to right: low responders 
to high responders). Color range: Brightest red (Change call increased (change p-value < 0.002) and Signal Log Ratio > 1): SLR 
= >2 (4× or higher), Black: SLR = 0 (no change); not visible as a consequence of the filtering process, Brightest green (Change 
call decreased (change p-value > 0.998) and Signal Log Ratio < -1): SLR < -2 (0.25× or smaller). Grey: no value (requirements 
for a reliably measured target not met). Calculated in Affymetrix comparison analysis (MAS5.0 algorithm) and at least one 
present call in the two síngle array analyses compared in the comparison analysis.BMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
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sion might sensitize endothelial cells to proapoptotic
stimuli present in the tumor microenvironment and
enhance NK cell cytotoxic activity against cancer cells [84].
YWHAH, or 14-3-3 eta, is a member of the dimeric 14-3-
3 family of signal transduction proteins that specifically
binds to phosphorylated serine on a variety of signalling
molecules, such as Bcl-2, MDMX, and Bax, thereby pro-
moting cell survival and acting antiapoptotic in several
tumor cells [85-87]. On the other hand, it is supposed to
be associated with tumorigenesis through its binding
interaction with gremlin1 [88]. Therefore the issue of fur-
ther studies should be awaited before interpreting this
finding.
PPP3CA (CCN1/Cyr61) is susceptible to various growth
factors and promotes cell proliferation, adhesion, and dif-
ferentiation and plays important roles in angiogenesis.
Additionally, PPP3CA has been associated with tumori-
genesis. It was reported that PPP3CA exerts its functions
via interacting with integrins as well as heparan sulfate
proteoglycan. By activating NF-kappaB and tyrosine
kinase signalling pathways, PPP3CA is not only able to
control cell growth, but also induce or suppress apoptosis
in a cell type-specific manner [89,90]. To the authors'
knowledge, it has so far not been reported in context with
liposarcoma or doxorubicin treatment.
Integrin B2 (ITGB2) is known to play a role in mediating
apoptosis [91] and chemotherapy resistance. Although it
is widely attributed to white blood cells, it is also
expressed in a variety of other benign and malignant cells
and seems to play a major role in cell invasion and migra-
tion [92].
Conclusion
In summary, pro- and antiapoptotic genes were found up-
as well as down-regulated with a dominance of up-regula-
tion of proapoptotic genes. The heterogeneous expression
profiles reflect the heterogeneous reaction of liposarco-
mas to doxorubicin therapy. A lot of genes we found dif-
ferentially expressed have not yet been associated with
apoptosis in liposarcoma or doxorubicin treatment.
Therefore it is not possible to relate our findings to other
studies. Our study shows that the low clinical response
rates of highly differentiated liposarcoma correlate to
minimal changes in the expression patterns and that only
high grade tumors, especially myxoid/roundcell and ple-
omorphic tumors, respond to doxorubicin on gene
expression level. In most cases, this response seems to be
Table 2: Summary of the genes that were up-regulated by doxorubicin treatment, including the log ratios
Samples with increased 
expression (n)
Gene symbol Mean log ratio Range of log ratio Samples with decreased 
expression (n)
Mean log ratio (Range of) log ratio
15 TNFRSF10B 1.96 0.41/4.49 0 - -
12 CDKN1A 1.85 0.59/4.10 1 - -0.99
12 GADD45A 1.44 0.58/2.88 1 - -0.59
12 FAS 1.36 0.27/3.87 1 - -0.28
12 CD40 0.94 0.39/2.11 0 - -
11 PAWR 1.16 0.33/2.51 1 - -1.25
11 TNFAIP3 2.16 0.23/3.67 0 - -
10 NFKBIA 2.04 0.43/3.34 2 -0.57 -0.45/-0.69
10 IER3 3.81 0.71/6.08 2 -0.60 -0.36/-0.84
10 PSEN1 0.84 0.23/1.61 2 -0.46 -0.46
10 RIPK2 2.02 0.42/3.65 2 -0.60 -0.46/-0.74
10 PEA15 0.61 0.23/0.96 1 - -0.68
10 BCL2A1 2.18 1.03/5.08 1 - -0.98
10 NGFB 3.06 0.40/5.80 1 - -1.12
10 BIRC3 2.06 0.63/3.23 1 - -0.93
10 CD44 1.57 0.26/3.09 1 - -0.56
9 MCL1 1.46 0.67/2.08 3 -0.65 -0.26/-1.21
9 HSPA9 1.25 0.46/1.95 2 -0.50 -0.21/-0.79
9 BTG1 0.77 0.31/1.50 1 - -1.06
9 HSP90B1 0.80 0.21/1.10 0 - -
9 SQSTM1 2.03 0.27/3.23 0 - -
9 PPP1R15A 3.16 0.65/4.40 0 - -
9 IRF1 1.38 0.60/2.94 0 - -
9 CYCS 0.82 0.34/1.37 0 - -
9 MDM2 1.76 0.33/3.58 0 - -
Negative log ratios stand for down-regulated genes.BMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
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Table 3: Summary of the genes that were down-regulated by doxorubicin treatment, including the log ratios
Samples with decreased 
expression (n)
Gene symbol Mean log ratio Range of log ratio Samples with increased 
expression (n)
Mean log ratio Range of log ratio
11 CD14 -2.99 -0.27/-5.38 0 - -
10 TIA1 -0.68 -0.24/-1.05 1 - 0.77
10 YWHAH -0.72 -0.27/-1.80 0 - -
10 PPP3CA -0.69 -0.34/-1.14 0 - -
10 ITGB2 -2.87 -0.58/-5.11 0 - -
9 PDGFRA -1.32 -0.42/-3.30 2 2.62 1.21/4.03
9 RASA1 -0.93 -0.42/-1.17 0 - -
8 LDHB -0.60 -0.32/-1.25 2 1.11 0.64/1,58
8 CSF1R -3.05 -0.63/-5.08 0 - -
8 RARA -0.95 -0.51/-1.23 0 - -
7 ANXA4 -1.10 -0.64/-1.16 4 1.37 0.84/2.33
7 CTSB -0.93 -0.23/-1.97 3 0.94 0.82/1.13
7 DAPK1 -1.35 -0.59/-2.07 2 1,40 1.19/1.60
7 CASP1 -1.69 -0.71/-2.90 2 1.44 0.97/1.90
7 PRF1 -1.68 -0.54/-3.68 2 0.79 0.67/0.91
7 EPHB4 -1.30 -0.68/-2.34 1 - 0.30
7 HCK -1.79 -0.39/-3.65 1 - 1.08
7 ESD -0.76 -0.44/-0.95 1 - 0.36
7 DHCR24 -1.97 -0.75/-4.34 0 - -
7 PPP1CB -0.99 -0.62/-1.56 0 - -
7 MYO18A/TIAF1 -1.23 -0.67/-2.02 0 - -
7 BIRC5 -2.95 -1.17/-4.91 0 - -
7 PDGFRB -1.28 -0.61/-2.26 0 - -
7 ATG5 -1.39 -0.61/-3.19 0 - -
7 DOCK1 -0.86 -0.40/-1.23 0 - -
7 PTPN13 -1.97 -0.69/-3.17 0 - -
7 BTK -1.78 -0.39/-3.28 0 - -
7 SYK -4.26 -0.34/-8.06 0 - -
Positive log ratios stand for up-regulated genes.BMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
Page 12 of 17
(page number not for citation purposes)
Heatmaps of expression changes of selected genes associated with apoptotic pathways after incubation with doxorubicin for 24  h ordered by responder group (5 a,b), grading (6 a,b), and histologic subtype (7 a/b) Figure 4
Heatmaps of expression changes of selected genes associated with apoptotic pathways after incubation with 
doxorubicin for 24 h ordered by responder group (5 a,b), grading (6 a,b), and histologic subtype (7 a/b). Expres-
sion changes as determined by comparison analysis were considered only if the probeset showed at least one P detection in 
untreated/treated sample pairs. Excluded expression changes are shown in grey. Only probesets with expression changes in 7 
or more samples are given. Horizontal rows represent individual probesets. Vertical columns represent individual samples (left 
to right: low responders to high responders); gene symbols are indicated to the right. Gene expression changes are indicated 
by a continuous scale; the brightest red indicating ≥ 4-fold up-regulation; and, brightest green ≥ 4-fold down-regulated gene 
expression relative to the untreated control sample.B
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Table 5: Summary of genes beyond the ones already mentioned in the text that were found to be up-regulated by doxorubicin treatment in more than 50% of the probes.
Gene symbol Gene name Probes upregulated Additional information Apoptotic function
PAWR PRKC (protein kinase C) apoptosis
WT1 (Wilms tumor gene) regulator protein
11 STS with high WT1 mRNA expression levels have 
poorer outcome than those with low levels [89,90].
Ecteinascidin that has been shown to be effective 
against STS also increases expression of PAWR [92].
PAWR inhibits the PKC (atypical protein kinase)-NF-
(kappa)B (nuclear factor-(kappa)B)-XIAP pathway [91].
proapoptotic
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 11 TNFAIP3 down-regulates the TNF-α-induced NFκB 
signalling pathway [93,94].
antiapoptotic
NFKBIA nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor alpha
10 The doxorubicin analogon DA-125 reduces 
proliferation in HT1080 fibrosarcoma cells through a 
NFKB dependent pathway [96,97].
MDM2 (upregulated in 9 samples in our series) is 
overexpressed in several liposarcoma subtypes [58] and 
increases NFKB activity in a p53 dependent manner and 
thereby leads to doxorubicin resistance [98].
proapoptotic/antiapoptotic
IER3 immediate early response 3 10 IER3 function is increased by p53, that is induced by 
doxorubicin. IER3 is involved in cell cycle arrest and 
programmed cell death [99,100].
proapoptotic
PSEN1 presenilin 1 10 Effects are mediated via Bcl-2 interaction [101]. proapoptotic
RIPK2 receptor-interacting serine-threonine kinase 2 10 RIPK2 is cell death inducing and NFKB activating, via 
caspase 1 activation [102,103].
proapoptotic
PEA15 phosphoprotein enriched in astrocytes 15 10 RPEA15 is regulating caspase-3 function in epidermal 
cells [104], but has not yet been associated with 
doxorubicin treatment or apoptosis in sarcoma cells.
antiapoptotic
BCL2A1 BCL2 (B-cell CLL/lymphoma 2)-related protein 
A1
10 BCL2A1 stabilizes the mitochondrial membrane 
[105,106].
antiapoptotic
NGFB nerve growth factor, beta polypeptide 10 NGF reduces apoptosis induced by chemotherapeutics 
in sarcoma cells [109].
antiapoptotic
BIRC3 baculoviral IAP repeat-containing 3 10 BIRC3 is associated with chemotherapy resistance in 
Ewing sarcoma, rhabdomyosarcoma [110] and prostatic 
cancer [111].
antiapoptotic
CD44 cell surface glycoprotein CD44 10 CD44 is a proapoptotic factor in FAS mediated 
apoptosis in sarcoma cells [112], but is also connected 
to cancer drug resistance [113].
CD44 has successfully been used as a target for 
liposomal encapsuled doxorubicin [114].
proapoptotic/antiapoptoticBMC Cancer 2008, 8:313 http://www.biomedcentral.com/1471-2407/8/313
Page 14 of 17
(page number not for citation purposes)
based on an increase of the extrinsic pathway such as
TRAIL Receptor 2 and FAS but also members of the intrin-
sic pathway such as BCL2A1 were found to be differen-
tially expressed. Interestingly several factors (NFKBIA,
GADD45A, RIPK2, and PAWR) point to the NFKB tran-
scriptional factor as possible mediator of doxorubicin
effects.
Our results indicate that gene expression profiling may be
a promising approach to improve the understanding of
the diverse modes of programmed cell death in liposar-
coma following doxorubicin treatment and can provide a
molecular basis for new chemotherapeutic strategies.
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